Journal of nuclear medicine : official publication, Society of Nuclear Medicine
-
Clinical Trial Controlled Clinical Trial
18F alpha-methyl tyrosine PET studies in patients with brain tumors.
We have developed 18F-labeled alpha-methyl tyrosine (FMT) for PET imaging. The aim of this study was to evaluate the clinical application potential of FMT for patients with brain tumors. ⋯ FMT, like other radiolabeled amino acids, can provide high-contrast PET images of brain tumors.